Monte Rosa Therapeutics, Inc. cash flow to debt ratio of -58.17% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Monte Rosa Therapeutics, Inc.'s free cash flow has decreased 172.35% from $38.01M last year to $-27.50M, signaling decreasing performance

Monte Rosa Therapeutics, Inc.'s debt to equity ratio is 0.08, which means that the company's assets are healthy financed, signaling financial stability.

Monte Rosa Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.19 last year to 0.08 today, signaling strengthened financials

Monte Rosa Therapeutics, Inc. has a net cash position, so leverage is healthy.

Monte Rosa Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Monte Rosa Therapeutics, Inc.'s profit margin has decreased (483.39%) in the last year from -96.14% to -560.85%, signaling decreasing performance

Monte Rosa Therapeutics, Inc.'s short-term assets of $393.19M exceed its short-term liabilities of $64.21M

Monte Rosa Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Monte Rosa Therapeutics, Inc.'s return on equity of -43.31%, is lower than 15.00%, indicating bad performance

Monte Rosa Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Monte Rosa Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Monte Rosa Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Monte Rosa Therapeutics, Inc. has negative free cash flow, indicating cash burn

Monte Rosa Therapeutics, Inc.'s yearly earnings has increased -46.87% since last year from $-72.70M to $-38.63M, signaling increasing performance

Monte Rosa Therapeutics, Inc.'s yearly revenue has increased 63.54% since last year from $75.62M to $123.67M, signaling increasing performance

ROIC -28.19% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Monte Rosa Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Monte Rosa Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Monte Rosa Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Monte Rosa Therapeutics, Inc. has insufficient data to evaluate this check.

Monte Rosa Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Monte Rosa Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Monte Rosa Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Monte Rosa Therapeutics, Inc. has insufficient data to evaluate this check.

Monte Rosa Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Monte Rosa Therapeutics, Inc. has a price-to-book ratio of 3.31x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Monte Rosa Therapeutics, Inc. has a price-to-sales ratio of 55.88x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue